Business InsiderTop News

Early data on Moderna’s COVID-19 vaccine insufficient: Stat News

imageStock Markets11 hours ago (May 19, 2020 05:35PM ET)

(C) Reuters. Moderna Therapeutics seen during COVID-19 in Massachusetts

(Reuters) – Data from a small, early-stage safety trial testing Moderna Inc’s (O:MRNA) experimental COVID-19 vaccine does not provide the critical data needed to assess its effectiveness, health-focused Stat News reported on Tuesday, citing experts.

The news publication’s report https:// pulled down shares of the Cambridge, Massachusetts-based biotech and erased modest gains on the benchmark S&P 500 index (SPX).

Moderna said on Monday the vaccine candidate, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers.

The news, while based on initial data from just eight people and not intended to assess the vaccine’s efficacy, nevertheless sent Moderna shares up 20% on Monday, and also pushed the broader markets higher.

Moderna later announced a stock sale that could raise about $1.5 billion, sending shares lower early on Tuesday.

Stat quoted health experts saying that Moderna had not provided enough data in its news release to judge the vaccine candidate.

Issues noted by Stat included:

– a lack of data about the responses to the medicine from other participants in the 45-subject study

– lack of information about the ages of the eight subjects whose antibodies were analyzed, an important question given the virus is particularly lethal to older people

– lack of comment from Moderna’s U.S. government partner on the vaccine, the National Institute for Allergy and Infectious Diseases

– the data is based on early responses to the vaccine, leaving unclear how long any immunity produced by the vaccine might last.

Moderna did not immediately respond to a Reuters’ request for comment.

The company’s shares closed down 10.4% at $71.67.

Early data on Moderna’s COVID-19 vaccine insufficient: Stat News

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles

Back to top button